Media

Anesiva to Present at BIO InvestorForum on October 11, 2007

SOUTH SAN FRANCISCO, Calif., Oct 05, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that John P. McLaughlin, the company's chief executive officer, will present at the Biotechnology Industry Organization's "BIO InvestorForum 2007" on Thursday, October 11, 2007 at 9:30 am PDT in San Francisco.

To access the live webcast or the subsequent archived recording, log on to http://www.anesiva.com and go to the Investors page, and click on Events. Please connect to Anesiva's website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Anesiva and its Diverse Portfolio of Pain Products

Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to be the leader in the development and commercialization of novel therapeutic treatments for pain. The company has one FDA-approved product, Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system, to reduce pain associated with peripheral venous access procedures in children three to 18 years of age. The second product in Anesiva's pipeline, Adlea(TM) (formerly 4975), has been shown to reduce pain after only a single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

SOURCE Anesiva, Inc.

http://www.anesiva.com

News Provided by COMTEX